Salts and solid forms of n-ethyl-2-(5-fluoro-1h-indol-3-yl)-n-methylethan-1-amine
AssigneeTerran Biosciences Inc.
InventorsMatthew DUNCTON, Samuel CLARK
Life of this patent
Estimating the term…
Abstract
Disclosed herein are salt and solid forms of N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine. The solid form may be a salt and/or a crystalline form of V-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine, such as a polymorph of N-eth-yl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine or a salt thereof. Also disclosed are methods for making the salts and solid forms and methods for administering the same. The solid forms of V-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine are useful for treating neurological disease and/or a psychiatric disorder in a subject.
Claims42
A compound, N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine, wherein the compound is in the form of a salt.
A solid form of (i) N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine or (ii) a N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine salt.
The compound of any of the preceding claims, wherein the solid form of N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine hydrochloride is a crystalline polymorph of N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine hydrochloride characterized by two or more, or three XRPD signals selected from the group consisting of 25.1 °2θ, 16.5 °2θ, and 26.2 °2θ (±0.2 °2θ;
- ±0.1 °2θ;
- or ±0.0 °2θ;
- Cu Kα1 radiation).
The compound of any of the preceding claims, wherein the solid form of N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine hydrochloride is a crystalline polymorph of N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine hydrochloride characterized by signals at 25.1 °2θ, 16.5 °2θ, and 26.2 °2θ (±0.2 °2θ;
- ±0.1 °2θ;
- or ±0.0 °2θ;
- Cu Kα1 radiation).
The compound of any of the preceding claims, wherein the solid form of N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine hydrochloride is a crystalline polymorph of N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine hydrochloride characterized by two or more, or three or more XRPD signals selected from the group consisting of 25.1 °2θ, 16.5 °2θ, 26.2 °2θ, 15.1 °2θ, and 17.0 °2θ (±0.2 °2θ;
- ±0.1 °2θ;
- or ±0.0 °2θ;
- Cu Kα1 radiation).
The compound of any of the preceding claims, wherein the solid form of N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine hydrochloride is a crystalline polymorph of N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine hydrochloride characterized by two or more, or three or more XRPD signals selected from the group consisting of 25.1 °2θ, 16.5 °2θ, 26.2 °2θ, 15.1 °2θ, 17.0 °2θ, 11.0 °2θ, and 27.8 °2θ (±0.2 °2θ;
- ±0.1 °2θ;
- or ±0.0 °2θ;
- Cu Kα1 radiation).
The compound of any of the preceding claims, wherein the solid form of N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine hydrochloride is a crystalline polymorph of N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine hydrochloride characterized by two or more, or three or more XRPD signals selected from the group consisting of 25.1 °2θ, 16.5 °2θ, 26.2 °2θ, 15.1 °2θ, 17.0 °2θ, 11.0 °2θ, 27.8 °2θ, 27.2 °2θ, 31.0 °2θ, and 26.8 °2θ (±0.2 °2θ;
- ±0.1 °2θ;
- or ±0.0 °2θ;
- Cu Kα1 radiation).
The compound of any of the preceding claims, wherein the solid form of N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine hydrochloride is a crystalline polymorph of N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine hydrochloride characterized by a XRPD diffractogram substantially similar to that shown in FIG. 1.
The compound of any of the preceding claims, wherein the solid form of N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine hydrochloride is a crystalline polymorph of N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine hydrochloride characterized by any combination of the XRPD peaks set forth in Table 1A.
A compound, N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine, in the form of a crystal, a salt, or both.
Dependencies are inferred from the claim text.